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Abstract: Rabies, the most fatal of all infectious diseases,
remains a major public health problem in developing
countries, claiming the lives of an estimated 55,000
people each year. Most fatal rabies cases, with more than
half of them in children, result from dog bites and occur
among low-income families in Southeast Asia and Africa.
Safe and efficacious vaccines are available to prevent
rabies. However, they have to be given repeatedly, three
times for pre-exposure vaccination and four to five times
for post-exposure prophylaxis (PEP). In cases of severe
exposure, a regimen of vaccine combined with a rabies
immunoglobulin (RIG) preparation is required. The high
incidence of fatal rabies is linked to a lack of knowledge
on the appropriate treatment of bite wounds, lack of
access to costly PEP, and failure to follow up with repeat
immunizations. New, more immunogenic but less costly
rabies virus vaccines are needed to reduce the toll of
rabies on human lives. A preventative vaccine used for the
immunization of children, especially those in high
incidence countries, would be expected to lower fatality
rates. Such a vaccine would have to be inexpensive, safe,
and provide sustained protection, preferably after a single
dose. Novel regimens are also needed for PEP to reduce
the need for the already scarce and costly RIG and to
reduce the number of vaccine doses to one or two. In this
review, the pipeline of new rabies vaccines that are in pre-
clinical testing is provided and an opinion on those that
might be best suited as potential replacements for the
currently used vaccines is offered.
Introduction
Rabies virus has a relatively simple RNA genome that encodes
five structural proteins. Of these, the rabies virus glycoprotein is
the only target for neutralizing antibodies (NAs), which provide full
protection against virus challenge [1–3]. Due to efforts spear-
headed by the World Health Organization (WHO), standardized
assays to measure NA titers to rabies virus are available [4]. Titers
equal to or more than 0.5 international units (IU), determined by
an infectious foci reduction assay against a WHO reference serum,
are considered protective in mammalian species tested to date.
Rabies virus has the highest fatality rate of all known human viral
pathogens. With less than a handful of exceptions, humans that
develop a symptomatic rabies virus infection inevitably die. Most of
thefewsurvivorshad extensivebraindamage followingtheinfection
[5]. One survivor receiving a novel treatment based on drug-
induced coma survived without long-term neurological damage [6].
Nevertheless, in subsequent studies this treatment failed to affect the
outcome of the disease in other rabies patients [7].
Humans are exposed to rabies, in general, through a bite by a
rabies virus–infected animal or through mucosal contact with
virus-contaminated fluids. In the United States, due to mandatory
pet vaccinations and public awareness of the potential to transmit
rabies virus through wild carnivores and bats, rabies virus
infections in humans are rare. In fact, the few human rabies
infections that are reported each year are caused by rabid bats
[8,9]. These transmissions, which generally result from minor skin
abrasions, are often overlooked. In developing countries, human
rabies, most commonly transmitted through the bite of rabid dogs,
is far more prevalent, causing 25,000–30,000 deaths each year in
India alone [10]. Half of the infections occur in children. In other
Asian countries, such as China, the incidence of rabies is
increasing [11]. Incidence rates are largely unknown for Central
Africa due to a lack of incidence reporting [12]. In developing
countries, dogs are commonly ownerless or community owned and
not vaccinated. Programs to vaccinate, sterilize, or euthanize stray
dogs have been attempted in these countries but have generally
failed [13]. Euthanasia of dogs is largely ineffective since a
decrease in the population results in increased breeding of the
remaining animals. Vaccination of the animals is only effective if
,70% of the dogs are vaccinated. Considering the large numbers
of stray dogs in countries such as India and Thailand, continued
vaccination of stray dogs poses major logistical problems that are
nearly insurmountable [14]. For the same reason, sterilization of
high enough numbers of stray dogs to reduce their population has
been impossible. Thus, rabies virus continues to spill over into the
human population [10].
Efficacious rabies vaccines for humans are commercially
available. In developed countries, the vaccines are based on fixed
strains of rabies virus, such as the Pitman Moore (PM) strain, the
Kissling strain of Challenge Virus Standard (CVS), or the Flury
low egg passage (LEP) fixed rabies virus strain [15]. These vaccine
preparations contain inactivated virus and some of them contain
adjuvant. They have to be given three times in a prophylactic
treatment to achieve protective immunity, which then, in general,
lasts for 3–4 years. Upon exposure to rabies virus, the vaccines
have to be given four to five times [15,16], and in cases of severe
exposure they have to be combined with rabies virus–specific
immunoglobulin (RIG). RIG, which should be of human origin
(HRIG), is in limited supply and plans to replace it with
monoclonal antibody preparations are ongoing [17]. Equine
rabies immunoglobulin (ERIG) preparations or purified F(ab)2
preparations of ERIG, which are digested antibodies from which
the immunogenic constant region is removed but which retains
binding to antigen, are also available. ERIG can cause serious side
effects including anaphylactic reactions and serum sickness. The
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anecdotally to vaccine failures, which may relate to the relative
short half-life of F(ab)2 fragments. The current post-exposure
prophylaxis (PEP), although highly efficacious and generally
tolerated, is very costly (approximately US$800–US$1,500 for
treatment including RIG) and requires the patient to seek medical
treatment four to five times.
Some of the less developed countries still use the Semple vaccine
derived from rabies virus propagated in the brains of infected
sheep or goats [19]. The Semple vaccine, in which the virus is
inactivated by phenol treatment, requires 14–21 daily injections.
The Semple vaccine is cheaper than vaccines produced from cell
or tissue culture but it has a potential for serious side effects in the
form of vaccine-induced auto-immune encephalomyelitis, which
afflicts ,1:200 vaccinees [20].
In part, the high incidence of rabies in spite of effective vaccines
is linked to ignorance of appropriate treatment [21]. Adults bitten
by a dog or parents of children bitten by a dog fail to appreciate
the potential for infection with a fatal virus. In some of the Asian
countries, patients are still seeking alternative treatments such as
herbal remedies to ward off a rabies virus infection. Otherwise,
vaccine failures are a consequence of inappropriate PEP caused
either by the health care provider’s lack of knowledge or by
financial restraints on the patient or his/her parents, the latter
being demonstrated by the fact that most rabies-related deaths in
India occur among economically disadvantaged families. In India,
wound cleaning is only performed in ,40% of patients that
present with a dog bite [22]. As already mentioned, RIG is costly
and in very short supply, and is thus commonly omitted. Most of
the RIG has to be given locally into the bite site and again, this is
not always done. The vaccine, depending on the regimen, has to
be given four to five times over 28 days. Often patients lack the
resources to seek medical attention repeatedly and thus only
receive the initial dose. Overall, in India only 47% of patients that
require vaccination receive it [22]. Again in India, a dog bites a
human every 2 seconds and every 30 minutes a human dies of
rabies [22]. The actual number may be by far higher as rabies is
not a reportable disease in India. In India, the annual cost due to
person-days lost because of animal bites is US$38 million, and the
cost of PEP is about US$25 million. A human that receives
vaccination after exposure loses, on average, 2.2 days of income
[22,23].
Considering the severity of rabies and its continued high
incidence in developing countries, development of novel vaccines
for rabies is warranted. A preventative vaccine used for
immunization of children, especially those is high incidence
countries, would be expected to lower fatality rates. Such a vaccine
would have to be inexpensive and provide sustained protection,
preferentially after a single dose application. For PEP, novel
regimens are needed that allow for a reduction of the scarce and
costly RIG and a lowering of the number of vaccine doses.
Methods
To compile this review, literature has been selected from
PubMed searches. Considering the multitude of manuscripts that
describe the new vaccine platforms, only a limited number of them
could be cited. Emphasis is given to reports that used standardized
assays to assess vaccine immunogenicity in comparison to
traditional vaccines, and that tested efficacy of preventative
vaccination or PEP in challenge models. In the end, the type(s)
of vaccine that is (are) the most promising of the candidates to
replace current regimens, is (are) the one(s) that outperforms all
current vaccines.
Vaccines to Rabies Virus
Traditionally, rabies vaccines have been generated by serial
passage of rabies virus in brain tissue or cell culture until
attenuated (live virus) or by inactivation of the virus (killed virus).
With advances in molecular virology, it is now possible to create
attenuated virus vaccines through genetic engineering, or to purify
viral antigens from highly efficient protein expression systems, or
to express individual viral antigens by inserting their genes into
different vaccine carriers. This has allowed the exploration and
analysis of immune responses to individual viral antigens, which in
turn has uncovered those most suited to induce protective
immunity. In the case of rabies virus, the prime immune correlate
of protection against the virus is the induction of NAs, and the only
viral antigen capable of achieving this is the rabies virus
glycoprotein. Accordingly, subunit vaccines that express this
antigen provide full protection to viral challenge [24,25]. Different
novel vaccines for rabies have been developed recently and their
advantages and disadvantages for use in humans are discussed
below.
Rabies Virus Vaccines Based on Reconstituted and
Traditionally Attenuated Viruses
Traditionally attenuated rabies viruses have been used success-
fully for oral immunization of animals in the wild that consume
baits containing the vaccine. A number of attenuated viral strains
have been used in baits for oral vaccination. All were derived from
a common ancestor, i.e., the Street Alabama Dufferin (SAD) [26],
including the Evelyn Rokitniki Abelseth strain, which has been
used, in particular, for vaccination of foxes [27]. This strain,
however, was found to cause fatal rabies in cats [28]. Traditional
rabies virus attenuation, in general, is linked to the amino acid
sequence of the viral glycoprotein (G). For example, a mutation in
position 333 of the glycoprotein where arginine is replaced by
glutamic acids generally attenuates the virus and provides the basis
for the apathogenic SAD strains [29]. Other mutations between
amino acid residues 164–303 can also reduce pathogenicity in
some strains [30]. Attenuation by a single amino acid exchange,
however, may not guarantee a stable nonpathogenic phenotype of
a rapidly mutating RNA virus. Indeed, it was found that rabies
virus attenuation through an amino acid substitution for Arg333
can revert back to pathogenicity upon serial passage of the virus in
mouse brain through the introduction of mutations at other
positions of the glycoprotein gene [31].
Advances in reverse genetics to produce reconstituted rabies
virus have allowed for targeted alterations of the genome of rabies
virus through expression of mutated genes. Using reverse genetic
techniques, a number of attenuated rabies viruses have been
generated and tested. One group developed a rabies virus based
on the Flury high egg passage (HEP) strain in which the gene
encoding the non-catalytic phosphoprotein (P) cofactor of the viral
polymerase was deleted. The resulting P-deleted virus was able to
grow in cell lines that constitutively provide the missing P antigen
for virus assembly and propagation. A P-deleted virus that cannot
replicate in cells is completely apathogenic. In mice, reconstituted
rabies virus lacking the P gene induces a strong NA response that
protects against challenge [32]. Similarly, deletion of the matrix
protein (M)-encoding gene from the RC-HL strain of reconstituted
rabies virus resulted in an apathogenic virus that retained its full
immunogenicity in relation to the glycoprotein [33]. The
immunogenicity of such deletion mutants was increased further
by insertion of an additional glycoprotein gene [34]. In mice,
antibody titers came up faster and the response was dominated by
antibodies of the IgG2a isotype, which is indicative of a T helper
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induced by the inactivated wild-type viral vaccine. Interestingly,
protection of mice was achieved with a single moderate dose of the
attenuated viruses that carried two glycoprotein genes. Again, it
should be stressed that the P-deleted and M-deleted viruses were
completely apathogenic even in immunodeficient animals. A
recent publication describes a triple glycoprotein variant rabies
virus that yielded promising results in mice [35]. It remains to be
shown that reconstituted mutant viruses expressing two or three
glycoprotein molecules are stable and that yields from large-scale
production are similar to those achieved with traditional vaccine
strains. Biodistribution studies have to be conducted to ensure that
the mutants do not reach the central nervous system and cause
neurotoxicity in larger mammals. Provided that the double or
triple glycoprotein expressing rabies virus mutants pass these tests
and show safety and immunogenicity in clinical trials, they would
be excellent candidates for both pre- and post-exposure immuni-
zation to rabies. Moreover, they would offer a number of cost-
saving advantages. The vaccine would not need to be inactivated,
which should reduce cost. In pre-exposure situations, the vaccine
would be expected to induce protective titers of NAs after a single
dose rather than after the three doses that are required for
currently available rabies vaccine. And finally, the more rapid the
onset of a response, the greater the possibility that the vaccine may
allow for a reduction in the use of RIG.
Novel Adjuvants
Commercially available rabies vaccines have to be given
repeatedly for prevention as well as for PEP, which adds to the
cost of rabies vaccination, both in terms of biologicals and
expenses associated with seeking medical treatment. An adjuvant
that would increase the immunogenicity of the vaccine and allow
for a reduction of numbers of doses would thus be very useful to
lessen the cost and reduce vaccine failures due to incomplete
vaccinations. Commercially available inactivated rabies virus
vaccines either do not contain adjuvant or are adjuvanted with
alum, which promotes a TH2 response favoring induction of
antibodies of the IgG1 isotype in mice [36]. In the last decade, our
understanding of basic immunological pathways that promote
immune responses has increased tremendously and we have
learned that activation of innate immune responses is a crucial first
step in the induction of adoptive immune responses. Signals
involved in activation of cells of the innate immune cells have been
identified, such as membrane-bound Toll-like receptors (TLRs)
and cytoplasmic NOD-like receptors [37]. This in turn has led to
the development of new types of adjuvants to replace alum, which
is well tolerated but not overly potent. Examples for such novel
adjuvants are CpG oligodeoxynucleotides (ODNs), which activate
the innate immune system upon binding to TLR-9. One group
tested the inactivated rabies vaccine adjuvanted with alum in
comparison to one adjuvanted with a CPG-ODN [38]. Three
doses of the latter induced rabies virus NA titers in mice that were
comparable to those induced with five doses of the alum-
adjuvanted vaccines. Although these results are promising, a word
of caution is needed. Mice and humans differ in their expression
pattern of TLR-9; results obtained in mice may thus not
necessarily translate to humans. If, on the other hand, human
trials show a dose-sparing effect of the already commercially
available vaccine preparations upon replacement of alum with
CpG-ODNs, such preparations clearly would be prime candidates
to replace currently used vaccines. In recent years, a number of
new adjuvants have been licensed or are in pre-clinical
development [39]. Their mode of action is being elucidated
[40], thus allowing for a more targeted formulation of vaccines.
Formulation of rabies vaccines with other second generation
adjuvants should be explored.
Protein Subunit Vaccines
A number of groups have tested vaccines administered orally
that are based on rabies virus glycoprotein purified from virus
[41], or expressed in insect cells infected with recombinant
baculovirus vectors [42], in yeast cultures that express the viral
glycoprotein [43], in glycoprotein cDNA-transfected cells [44], or
in transgenic plants [45]. These experiments met with variable
success. This is not surprising considering the structural complex-
ity of the rabies virus glycoprotein, which carries two branches of
N-linked oligosaccharides [46]. Most of the rabies virus NAs bind
to conformation-dependent epitopes on the native glycoprotein
that appear to be expressed preferentially by multimeric forms of
the protein, rather than by monomeric forms of cleaved
glycoprotein that is secreted by infected cells or that is commonly
produced by expression systems. Although yeast has been used
successfully to develop proteins such as hepatitis B virus surface
antigen vaccine, expression of the rabies glycoprotein in yeast
resulted in an incorrectly folded protein that was only poorly
immunogenic [43].
Upon infection with a recombinant baculovirus, insect cells
produced a rabies glycoprotein that was antigenically conserved
compared to the native protein, although the recombinant
glycoprotein was slightly smaller in size, suggesting it might have
different post-translational modifications. Immunization of mice
with rabies glycoprotein–producing insect cells caused induction of
protective NA titers [42]. In raccoons, repeated oral immunization
with rabies virus glycoprotein–containing cell lysate induced rabies
virus NA titers that protected most but not all of the animals from
lethal challenge [47]. For human vaccination, the use of cells or
cell lysate would not be appropriate. Purification of glycoproteins
is formidable and cumbersome, often ineffective, and costly.
Although purified protein vaccines are in general well tolerated, it
is unlikely that a baculovirus-derived rabies glycoprotein vaccine
would be less costly than current vaccines.
Other investigators have focused on expressing the rabies virus
glycoproteins in plants. The rabies virus glycoprotein expressed
within tobacco leaves was shown to be authentically glycosylated.
It was also immunogenic and induced protection in intramuscu-
larly immunized mice [48]. Similarly, a single oral immunization
of mice with transformed maize kernels containing rabies
glycoprotein induced protection against a lethal challenge [49].
Production of medicinal proteins in plants has the clear advantage
that large amounts of protein can be generated at a low cost. For
the generation of a vaccine to be given by injection, the cost of
producing the protein in plants is offset by a need for purification
of the protein at relatively high cost. Intuitively, far more attractive
is the concept to generate edible vaccine antigens expressed by
vegetable or fruits that are part of the human diet. Techniques
have been developed to generate transgenic bananas, potatoes,
tomatoes, spinach, and the like that express foreign proteins, and
these techniques are being refined to ensure more authentic post-
translational modifications. Oral immunization has been successful
with whole or intact viruses that typically resist degradation in the
digestive tract. One prime example is the live poliovirus vaccine
that was given to children on lumps of sugar. Other less hardy
viruses, such as the adenovirus (Ad) vaccines that were given to the
US military, had to be encapsidated to protect them against acid
degradation and to retain immunogenicity [50]. Oral rabies
vaccines that are given in baits to raccoons, foxes, and other free-
ranging animals do not induce immune responses in the intestine
but rather infect cells of the oral cavity, which is rich in lymphatic
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detail, glycoprotein-containing insect cells or plant cells presum-
ably also require presentation of the antigens by cells of the oral
cavity. Would it be expected that successful oral immunization of
animals readily translates to humans? Considering that humans
vary widely in their eating habits, similar to animals—some chew
carefully, others gulp down big chunks of food—the simple feeding
of rabies virus glycoprotein-containing plants to achieve protective
immunity against rabies is unlikely to yield uniform responses.
One also needs to consider how the immune system may react if
some of the antigen successfully passes the stomach, as could
happen in humans with low stomach acid. The intestinal immune
system, which is targeted by antigens that pass through the
stomach, is substantially different from the systemic immune
system, which responds to antigens that are directly injected into
muscle or skin. The intestinal immune system is constantly
bombarded by harmless antigen present in food in addition to
harmful antigens of pathogens. Thus, the intestinal immune
system has to balance between tolerating beneficial antigens while
still combating pathogens. Proteins present in the intestine are
viewed as beneficial and thus induce systemic unresponsiveness, a
phenomenon termed oral tolerance [52]. If and to what degree an
edible rabies virus glycoprotein vaccine may induce oral tolerance
clearly needs to be investigated before such vaccines can even
enter clinical trials for oral immunization of humans.
As a rather clever variation of edible vaccines, another group
developed plant hybrid viruses based on alfalfa mosaic virus or
tobacco mosaic virus [53]. The coat proteins of these viruses were
genetically modified to express a peptide composed of antibody
binding sequences of the rabies virus glycoprotein and the
nucleoprotein. Although these vaccines are not classical protein
vaccines, they are included in this part of the review since they
represent virus particles that carry and present the rabies virus
antigen on their surface, unlike recombinant viral vector vaccines
that carry the genetic information of rabies virus. The viruses were
propagated in tobacco or spinach plants, respectively, and then
purified and given three times to mice. The mice fed the plant-
derived protein were protected against rabies virus challenge. The
vaccine produced in spinach was also tested in humans. Some of
the human volunteers that already had NAs to rabies virus showed
a slight increase in NA titers upon repeated ingestion of virus-
containing spinach leaves. Seronegative humans did not develop
detectable titers of rabies virus NAs after being fed several doses of
the spinach vaccine, although three out of nine appeared to have
been primed as they developed higher than expected NA titers
after inoculation with one dose of a commercially available rabies
virus vaccine [53]. Overall, this approach, although intellectually
very appealing, needs to be refined substantially before it becomes
a viable option for an alternative rabies vaccine.
DNA Vaccines
A large number of publications that address the development of
novel rabies vaccines focus on the use of plasmid vectors, also
termed DNA vaccines [54–57]. DNA vaccines are appealing for
many reasons: they are extraordinarily stable, they only induce
immune responses to the wanted antigen, and they carry their own
adjuvant in the form of unmethylated CpG sequences present in
the bacterial backbone of the vector. They are also easy to
generate and their scale-up production is more uncomplicated and
cost effective than that of purified protein vaccines or vaccines that
require mammalian tissue cell culture. DNA vaccines are safe, they
do not integrate into the host cell genome, they do not induce
antibodies to DNA or autoimmune diseases, and they only elicit
mild local reactions, as shown in numerous clinical trials. Overall,
results have shown that immunization with plasmid vectors
resulted in the slow and modest induction of rabies virus NAs.
Responses to one dose of plasmid vector were well below those to
one dose of a traditional inactivated rabies virus vaccine [57].
Responses could be improved by repeated immunization [57], by
the use of adjuvants such as other vectors encoding cytokines [58],
or monophosphorolipid A [59]. Responses were increased by
intradermal rather than intramuscular immunization or by
application of the vector with a gene gun, which propels DNA-
loaded gold particles directly into the cells of the skin [59]. DNA
vaccines were tested in larger species and reports showed
protection of dogs and cats with DNA vaccines given at moderate
doses [60,61]. One group showed induction of NA responses and
protection against challenge in nonhuman primates [62]. Others
have explored the use of replicon-based self replicating DNA
vaccines derived from an alphavirus, i.e. Sindbis virus [63].
Although rabies virus NA responses to the replicon DNA vaccine
given twice exceeded those to a conventional DNA vaccine, they
did not reach the levels obtained by two doses of a conventional
whole virus vaccine.
One group reported on successful post-exposure vaccination of
rabbits and mice with DNA vaccines given intranasally [64]. In
this report, all of the animals that received the DNA vaccine were
protected, while one out of eight rabbits that received a
commercial human rabies vaccine died. Similar results were
obtained for PEP of mice. These results have to be viewed with
caution. The plasmid DNA was found in numerous areas of the
brain after immunization and the authors concluded that the local
immune response initiated within the brain by the DNA vaccine
was linked to the observed efficacy of the vaccine. Adaptive
immune responses are not initiated in the brain but rather in
lymph nodes, which are not present in the central nervous system.
The presence of DNA vectors in the central nervous system in the
study is worrisome and difficult to understand. The intranasal
immunization with the DNA vaccine was controlled for by an
intramuscular injection of saline. This is not an appropriate
control, as it does not take into account DNA vaccine-driven
activation of the innate response that may have contributed to
protection. Post-exposure vaccination of nonhuman primates,
combined with RIG, resulted in partial protection [65].
In spite of these two reports, the slow onset of an immune
response to the transgene product of a DNA vaccine observed by
numerous investigators using different routes of administration
precludes their use for post-exposure immunization, when
immune responses have to be induced rapidly to ward off a
symptomatic rabies virus infection of the central nervous system.
Are they useful for preventative vaccination to reduce the
incidence of rabies infections in highly endemic resource-poor
regions? A number of DNA vaccines expressing antigens from
other viral pathogens, which can be prevented by NAs, have
undergone clinical testing. Examples are DNA vaccines expressing
the hemagglutinin of influenza A virus or the surface antigen of
hepatitis B virus [66]. Results were uniformly disappointing; the
DNA vaccines applied in various ways, including injection by
syringe or administration by gene gun, either failed to induce a
detectable antibody response or the antibody response was very
low. Lack of uptake of DNA vaccines by cells at the inoculation
site has been identified as a barrier to efficient antigen production
in vivo, which in turn is needed for an optimized immune
response. DNA uptake can be improved technically by applying
short electrical pulses, i.e., electroporation, to the DNA vaccine–
injected muscles. DNA vaccination combined with electroporation
has yielded very promising results in experimental animals, in
which antibody titers induced by this method exceed those
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[67]. Several clinical trials have been started to assess the
effectiveness of electroporation of DNA vaccines in humans;
results are not yet available. Hence, it remains to be established if
DNA vaccination by electroporation is effective for prevention of
rabies in humans.
Recombinant Viral Vector Vaccines
Viral vectors, based on a variety of different parental viruses
carrying the gene for the rabies virus glycoprotein under a suitable
promoter, have been explored as vaccine carriers. Although viral
vector vaccines offer many advantages, including faithful expres-
sion of foreign viral antigens in mammalian cells, they have one
disadvantage. That is, existing NAs to the parental virus in the
target species can inhibit the uptake of recombinant viral vectors
and hence production of the vaccine antigen. This reduces, or in
the extreme even abolishes, expression of the transgene product
and thus impairs the immunogenicity and efficacy of the viral
vector vaccine. Many viral vectors are based on pathogens that are
common in the target species. For example, vectors based on the
human adenovirus serotype 5 (AdHu5) have undergone extensive
testing as a vaccine carrier in humans [68], while those based on
canine adenovirus 2 are being explored for use in dogs [69]. Both
species commonly have NAs to either virus [70,71]. The use of
vectors based on common pathogens needs to be explored in the
presence of vector-specific NAs to gain a realistic assessment of
their immunogenicity in their target species.
Poxvirus Vectors
A vaccinia virus recombinant expressing the rabies virus
glycoprotein (VRG) is being used commercially for oral immuni-
zation of wildlife. The recombinant is based on the highly
reactogenic Copenhagen strain of vaccinia virus, which is not
suited for vaccination of humans [72]. More attenuated poxviruses
have been developed, such the modified vaccinia virus Ankara
(MVA), which upon numerous passages in cells deleted ,15% of
the genome of the parental virus. MVA is replication incompetent
in most cells and it is well tolerated, even by humans that have
underlying conditions that would preclude them from vaccination
with vaccinia virus. MVA vectors expressing the rabies virus
glycoprotein were tested in mice [73]. Results clearly showed that
the MVA vectors were less immunogenic than the VRG vaccine.
In dogs and raccoons that already had NAs to rabies virus, the
MVA vector induced an anamnestic response if given intramus-
cularly, but was ineffective upon oral administration. Overall,
these results suggest that MVA vectors are not suited to replace
currently available conventional or recombinant vaccines for use
in animals or humans.
Herpesvirus Vectors
A vector based on an attenuated porcine herpesvirus 1, also
termed pseudorabies virus, expressing the rabies virus glycoprotein
was tested in dogs [74]. Pseudorabies virus causes abortions in
sows and a fatal disease in piglets. An attenuated virus, used as a
vaccine in pigs, is efficacious and safe. Dogs and cats can become
infected with pseudorabies virus and the infection in these species
is commonly fatal. As pigs are the only reservoir for pseudorabies
virus, prevalence rates of NAs to this virus that may interfere with
a recombinant pseudorabies virus-based vaccine would be
expected to be low in other species, such as dogs or humans.
Oral immunization with the pseudorabies virus vaccine expressing
the rabies virus glycoprotein resulted in protective antibody titers
in dogs. Nevertheless, although the vaccine virus was applied at
high doses, NA titers were lower than those obtained with a
conventional vaccine [74].
Ad Vectors
A multitude of Ads have been isolated from different species
including humans, chimpanzees, other nonhuman primates,
bovines, canines, birds, snakes, and frogs. Phylogenetic analysis
showed that Ads can be grouped into three major trees that share
common ancestors [75]. Human Ads are closely related to those
isolated from chimpanzees. They are also closely related to Ads
isolated from dogs, mice, pigs, and horses. Ads isolated from
bovines fall into two trees; some are related to human Ads, others
are more closely related to those isolated from goats, sheep, deer,
and ducks. Ads isolated from fowl are grouped with those isolated
from amphibians [75]. Ads are subdivided not only according to
the species from which they originated, but also into families, such
as families A–E for human Ads, and into serotypes, which are
defined by the specificity of NAs.
Ad vectors derived from different serotypes and species have
been tested extensively as vaccine carriers for a variety of different
pathogens. Ads are ubiquitous pathogens and the prevalence of
NAs to the more common serotypes is high in humans as well as
animals. NAs inhibit or weaken infection of the host cells by the
corresponding Ad or by a vaccine vector based on this Ad,
resulting in reduced immune responses to the encoded antigen. Ad
vectors based on serotypes that are common in a given target
species should thus not be used as vaccine carriers in this species,
as the desired immune response will be highly variable depending
on the presence and magnitude of Ad-specific NAs in the vaccine
recipient.
Ad Vectors Based on the Human Serotype 5 (AdHu5)
Most vaccine studies conducted to date have been based on E1-
deleted and thus replication-defective AdHu5 vectors [76–78].
Even if given at moderate doses, E1-deleted AdHu5 recombinants
induce high B and CD8
+ T cell responses in experimental animals,
and in humans tested thus far. The immune responses to the
transgene product of the Ad vector far surpass those achieved with
other types of subunit vaccines, such as vaccinia virus recombi-
nants or DNA vaccines [77,78]. In a mouse model for preventative
vaccination to rabies, full and long-lasting protection against a
severe challenge with rabies virus could be induced with a single
moderate dose of an E1-deleted AdHu5 vaccine expressing the
rabies virus glycoprotein [78]. The high immunogenicity of Ad
vectors relates in part to the non-cytopathic nature of such E1-
deleted viruses, resulting in sustained antigen expression [78]. In
addition, the vectors persist at very low levels in T lymphocytes in
a transcriptionally active form [79], which allows for and supports
a sustained response. Replication-competent Ad vectors, in which
expression of the rabies virus glycoprotein is either driven by an
endogenous Ad promoter or by the SV40 promoter inserted into
the vector, which in many cell types is significantly weaker than
the cytomegalovirus promoter used for replication-defective Ad
vectors, have been tested in experimental animals [80,81]. The
replication-competent vectors induced protective NA titers to
rabies virus in mice as well as in skunks; nevertheless, the vectors
were less efficacious compared to replication-defective vectors
expressing a closely related transgene product. Also, the use of
replication-competent adenovirus vectors may pose risks, especial-
ly to immunocompromised individuals.
Although E1-deleted AdHu5 vectors have yielded highly
promising results as vaccines in rodents, primates, and canines,
the pre-existing immunity was shown to interfere with the efficacy
of such vaccines [82,83]. Nearly all adults have binding antibodies
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showed that ,45% of human adults in the US, ,80% of the
human population in Thailand, and up to 90% in Central Africa
have detectable titers of virus NAs to AdHu5 virus [71]. We
showed previously that the B cell response in pre-exposed mice
could be rescued by increasing the dose of the adenoviral vaccine
or by using a DNA vaccine for priming [77,78]. Increasing the Ad
vaccine dose may be problematic, as doses equal to or above 10
11
Ad particles (vps) were shown to have systemic side effects (fever) in
clinical trials [84]. Oral immunization was also shown to overcome
the effect of pre-existing immunity in rodents [77], but we found
that this route of immunization was not effective in nonhuman
primates. It has been suggested that E1-deleted AdHu5 vectors
could be used during early infancy before children become
naturally infected [85]. A study conducted in India showed that
only 30%–40% of infants below the age of 18 months had NAs to
AdHu5 virus, and the prevalence of such antibodies rose sharply to
,70% in children between 19 and 24 months of age. Although
AdHu5 vectors were shown to be immunogenic in neonatal
animals [86], their use in human infants should thus be
discouraged.
In a recent phase IIb clinical trial, termed the STEP trial,
AdHu5 vectors were tested as CD8
+ T cell inducing vaccines to
HIV-1 [68,87]. The trials enrolled individuals with low or absent
baseline titers of virus NAs to AdHu5 virus and individuals with
moderate to high titers of such antibodies. The trials were powered
to allow for testing of vaccine efficacy in reducing HIV-1
acquisition and viral set point loads. The STEP trial, which had
planned to enroll 3,000 participants, was stopped and unblinded
before enrollment was completed, as an interim analysis showed
that the vaccine lacked efficacy and showed a trend for higher
HIV-1 acquisition in vaccinated individuals that were seropositive
for AdHu5 virus at the onset of vaccination. It remains to be
shown whether AdHu5 vaccination of AdHu5 seropositive
individuals results in an increased risk for HIV-1 acquisition.
Under the assumption that the increased HIV-1 acquisition rate
was related to the vaccine carrier, i.e., the AdHu5 vector rather
than the HIV-1 vaccine antigens, such vectors or vectors that
contain parts of AdHu5 that provide targets for NAs should not be
used in humans who may be at risk for HIV-1 infections.
E1-Deleted Ad Vectors Based on Rare Human Serotypes
Vectors based on rare serotypes of human Ads were developed
to circumvent vaccine failures caused by pre-existing NAs to the
vaccine carrier. Examples of such rare serotypes include AdHu35,
AdHu48, AdHu11, or AdHu26 viruses, and vectors based on these
serotypes have been tested for antigens of HIV-1 or tuberculosis
[88,89], but not yet for those of rabies virus.
Ad Vectors Based on Chimpanzee-Derived Serotypes
We tested several alternative adenoviral vaccine carriers based
on viruses that were isolated from chimpanzees [83,90–92]. We
chose isolates from chimpanzees assuming that these Ad serotypes
would more closely resemble the well characterized human
serotypes with regard to growth characteristics (which influences
vaccine yield), tropism and receptor utilization (both of which
influence immunogenicity), and transcomplementation with E1
gene products derived from AdHu5 virus. This latter point is
important for logistic reasons. Mammalian cell lines that
transcomplement E1 gene products of AdHu5 to E1-deleted
adenoviral recombinants are available. Generation of such
packaging cell lines, especially for eventual production of GMP
vaccine lots, is extremely labor-intensive and time consuming. E1-
deleted Ads that can be grown on the available packaging cell lines
(that carry the E1 gene products of AdHu5 virus) can thus be
developed much more rapidly. Using heterologous E1 gene
products for transcomplementation has an added advantage; the
sequences flanking the E1 gene in Ad show limited homology
between different serotypes. The risk of contamination of E1-
deleted adenoviral vaccine stocks with replication-competent virus
that arises upon homologous recombination of the vaccine with
the E1 of the packaging cell line is thus virtually absent if both are
derived from different serotypes.
We tested four chimpanzee adenovirus (AdC) serotypes as
vaccine carriers for the rabies virus glycoprotein. Three of those,
termed AdC68, AdC7, and AdC6, can be grouped within
subfamily E of human Ads and use the coxsackie-Ad receptor
(CAR) for cell attachment; the other, termed AdC1, belongs to
subfamily B2 and uses CD46 as its receptor for cell entry. Most
humans residing in the US or Thailand do not carry NAs to the
AdC viruses. Prevalence rates of NAs to AdC6 are markedly
higher in some countries of sub-Saharan Africa, presumably
reflecting spillover infections from chimpanzees [71]. AdC vectors
were found to be highly immunogenic in mice and nonhuman
primates. As was shown for human serotype Ad vectors, the CAR-
binding AdC vectors outperformed the CD46-binding AdC1
vector.
Th eim m u n og e n ici tyo ft h eE 1 -de letedAdCvaccinecarriersis
not strongly impaired by pre-existing immunity to common
human serotypes of Ad, at least in mice [92]. When tested as
vaccine carriers for the rabies virus glycoprotein, the AdC
vectors were shown to induce sustained and protective titers of
rabies virus NAs after a single dose in mice. A single dose of the
vaccines induced protective titers of NAs after intramuscular,
oral, or intranasal immunization in adult as well as neonatal
mice [83,93,94]. Titers were sustained in mice and showed no
decline within the first 20 months after immunization (Z. Q.
Xiang and H. C. Ertl, unpublished data). Additional studies are
needed to confirm the longevity of protective responses in other
species.
Ad Vectors Based on Dog-Derived Serotypes
Replication-defective vectors based on canine Ad serotype 2
have been generated. Upon oral immunization with high doses of
the vector given in baits, most of the dogs seroconverted [95].
Although titers induced by the vaccines were low, they were
remarkably sustained, yielding protection to all of the serocon-
verted dogs for at least 2 years. It should be pointed out that
canine Ad2 is one of the causative agents of kennel cough and a
component of available vaccines used for vaccination of puppies.
The use of such vectors may not be optimal for immunization of
dogs that may be pre-immune to canine Ad2 due to vaccination or
natural infections.
A replication-competent Ad vector from the canine Ad
serotype 2 was tested in pigs in comparison to one dose of a
commercial vaccine [96]. Pigs immunized orally or intranasally
failed to develop antibodies to rabies virus, even at a high dose of
the virus. Upon systemic immunization with the Ad vector, titers
came up markedly slower and were lower than upon immuni-
zation with the commercial rabies vaccine. It should be pointed
out that a replication-competent canine Ad vector might not
replicate in swine, even though porcine and canine Ads are
closely related. Lack of replication in swine, which may explain
the disappointing immunogenicity of the replication competent
vector, was not formally tested for, but was suggested by the
complete lack of shedding of virus upon oral or intranasal
application.
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One group tested an Ad vector derived from an avian serotype,
i.e., Celo virus, as a vaccine carrier to elicit an anti-rabies immune
response in mice [97]. Repeated vaccination protected less than
50% of the mice, indicating that such vectors lack the high
immunogenicity of Ad vectors isolated from mammals.
Summary
Clearly, the global pipeline for new rabies vaccines looks
impressive at first glance, although it should be pointed out that
most of these novel vaccines have not yet undergone extensive pre-
clinical testing or comparison to commercially available vaccines
using standardized reference sera to measure neutralization titers,
let alone clinical testing. Rabies is a nearly always fatal disease that
still kills more than an estimated 50,000 people each year and
inflicts costs in the millions of dollars, but in spite of this remains
an orphan disease. Rabies is a disease that affects mainly the
poorest of the poor. Developed countries with resources for
research and development of novel vaccines do not view rabies as
a priority, for after all an efficacious vaccine is available to those
that can afford it. The vaccine industry in developed countries has
little incentive to develop a new vaccine to rabies for resource-poor
countries, and the fledging vaccine companies in developing
countries lack the infrastructure to generate novel vaccines, and
are thus focused on the manufacture of traditional vaccines.
Notwithstanding this, human rabies vaccines are needed for two
applications: vaccines for large-scale preventative vaccination of
children in resource-poor countries with a high incidence rate of
rabies, and vaccines for PEP for use after exposure to a rabid
animal. Currently, the same vaccines are used for both
applications, but one could well envision the use of different
vaccines and vaccine prototypes to address these critical objectives.
A vaccine for preventative vaccination given along with other
vaccines to children between the ages of 1 and 2 years would need
to induce sustained protection for at least 10–20 years after a single
dose. Such a vaccine would have to be inexpensive, safe, and
acceptable to parents. The only vaccines that could potentially
induce such a sustained response after a single immunization are
those based on Ad vectors. To avoid interference with endogenous
NAs to the vaccine carrier, Ad vectors should be based on rare
human serotypes or on nonhuman serotypes such as those from
chimpanzees.
For PEP, vaccines need to rapidly induce protective titers of
rabies-specific NAs. An improved PEP rabies vaccine should be
inexpensive and reduce the number of doses from the currently
used four to five dose regimens. Ideally, such a vaccine would also
require less or no RIG. Vaccines based on gene transfer
technology inevitably delay immune responses, as they require
initial transcription and translation before the vaccine antigen is
expressed. DNA vaccines and viral recombinant vaccines may thus
not be optimal for PEP. Better adjuvants would increase the
immunogenicity of current vaccines and should clearly be pursued
in more depth with the new vaccines in development. Attenuated
rabies mutants, in which crucial genes are deleted and replaced
with a second glycoprotein gene, were shown pre-clinically to
induce more potent immune responses than traditional vaccines
and responses came up more rapidly. Such viral mutants may be
highly suited to replace the current vaccines for PEP.
References
1. Schumacher CL, Dietzschold B, Ertl HC, Niu HS, Rupprecht CE, et al. (1989)
Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of
rabies. J Clin Invest 84: 971–975.
2. Wunderli PS, Shaddock JH, Schmid DS, Miller TJ, Baer GM (1991) The
protective role of humoral neutralizing antibody in the NIH potency test for
rabies vaccines. Vaccine 9: 638–642.
3. Xiang ZQ, Knowles BB, McCarrick JW, Ertl HC (1995) Immune effector
mechanisms required for protection to rabies virus. Virology 214: 398–404.
4. Blancou J, Aubert MF, Cain E, Selve M, Thraenhart O, et al. (1989) Effect of
strain differences on the potency testing of rabies vaccines in mice. J Biol Stand
17: 259–266.
5. Winkler WG, Fashinell TR, Leffingwell L, Howard P, Conomy P (1973)
Airborne rabies transmission in a laboratory worker. Jama 226: 1219–1221.
6. Willoughby RE, Jr., Tieves KS, Hoffman GM, Ghanayem NS, Amlie-
Lefond CM, et al. (2005) Survival after treatment of rabies with induction of
coma. N Engl J Med 352: 2508–2514.
7. Jackson AC (2009) Update on rabies diagnosis and treatment. Curr Infect Dis
Rep 11: 296–301.
8. (1998) From the Centers for Disease Control and Prevention. Human rabies–
Texas and New Jersey, 1997. Jama 279: 421–422.
9. (1999) Human rabies–Virginia, 1998. MMWR Morb Mortal Wkly Rep 48: 95–97.
10. Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Ashwath
Narayana DH, et al. (2007) Assessing the burden of human rabies in India: results
of a national multi-center epidemiological survey. Int J Infect Dis 11: 29–35.
11. Hu R, Tang Q, Tang J, Fooks AR (2008) Rabies in China: An Update. Vector
Borne Zoonotic Dis.
12. Dodet B, Adjogoua EV, Aguemon AR, Amadou OH, Atipo AL, et al. (2008)
Fighting rabies in Africa: the Africa Rabies Expert Bureau (AfroREB). Vaccine
26: 6295–6298.
13. Jackson AC, Warrell MJ, Rupprecht CE, Ertl HC, Dietzschold B, et al. (2003)
Management of rabies in humans. Clin Infect Dis 36: 60–63.
14. Kasempimolporn S, Sichanasai B, Saengseesom W, Puempumpanich S,
Sitprija V (2008) Stray dogs in Bangkok, Thailand: rabies virus infection and
rabies antibody prevalence. Dev Biol (Basel) 131: 137–143.
15. Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, et al.
(2008) Human rabies prevention–United States, 2008: recommendations of the
Key Learning Points
N High incidence rates of rabies in developing countries
N Reasons for the ongoing high human fatality rates for
rabies
N Correlates of protection against rabies virus
N Post-exposure versus preventative vaccination to rabies
virus
N Different vaccine prototypes for rabies in pre-clinical
development
Key Papers
1. Warrell MJ (2003) The challenge to provide affordable
rabies post-exposure prophylaxis. Vaccine 21: 706–709.
2. Ichhpujani RL, Mala C, Veena M, Singh J, Bhardwaj M, et al.
(2008) Epidemiology of animal bites and rabies cases in
India. A multicentric study. J Commun Dis 40: 27–36.
3. Cenna J, Tan GS, Papaneri AB, Dietzschold B, Schnell MJ,
et al. (2008) Immune modulating effect by a phospho-
protein-deleted rabies virus vaccine vector expressing
two copies of the rabies virus glycoprotein gene. Vaccine
26: 6405–6414.
4. Wang X, Bao M, Wan M, Wei H, Wang L, et al. (2008) A
CpG oligodeoxynucleotide acts as a potent adjuvant for
inactivated rabies virus vaccine. Vaccine 26: 1893–1901.
5. Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, et al.
(2002) Novel, chimpanzee serotype 68-based adenoviral
vaccine carrier for induction of antibodies to a transgene
product. J Virol 76: 2667–2675.
www.plosntds.org 7 September 2009 | Volume 3 | Issue 9 | e515Advisory Committee on Immunization Practices. MMWR Recomm Rep 57:
1–28.
16. (2007) Rabies vaccines. WHO position paper. Wkly Epidemiol Rec 82: 425–435.
17. Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, et al. (2008) First
administration to humans of a monoclonal antibody cocktail against rabies virus:
safety, tolerability, and neutralizing activity. Vaccine 26: 5922–5927.
18. Fernandes A, Kaundinya JO, Daftary G, Saxena L, Banerjee S, et al. (2008)
Chromatographic purification of equine immunoglobulin G F(ab)2 from plasma.
J Chromatogr B Analyt Technol Biomed Life Sci 876: 109–115.
19. Warrell MJ (2003) The challenge to provide affordable rabies post-exposure
treatment. Vaccine 21: 706–709.
20. Piyasirisilp S, Schmeckpeper BJ, Chandanayingyong D, Hemachudha T,
Griffin DE (1999) Association of HLA and T-cell receptor gene polymorphisms
with Semple rabies vaccine-induced autoimmune encephalomyelitis. Ann
Neurol 45: 595–600.
21. Ichhpujani RL, Mala C, Veena M, Singh J, Bhardwaj M, et al. (2008)
Epidemiology of animal bites and rabies cases in India. A multicentric study.
J Commun Dis 40: 27–36.
22. Menezes R (2008) Rabies in India. Cmaj 178: 564–566.
23. (2005) WHO Expert Consultation on rabies. World Health Organ Tech Rep
Ser 931: 1–88, back cover.
24. Wiktor TJ, Macfarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, et al. (1984)
Protection from rabies by a vaccinia virus recombinant containing the rabies
virus glycoprotein gene. Proc Natl Acad Sci U S A 81: 7194–7198.
25. Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, et al. (1994)
Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene
induces protective immunity against rabies virus. Virology 199: 132–140.
26. Cliquet F, Aubert M (2004) Elimination of terrestrial rabies in Western
European countries. Dev Biol (Basel) 119: 185–204.
27. Bankovskiy D, Safonov G, Kurilchuk Y (2008) Immunogenicity of the ERA G
333 rabies virus strain in foxes and raccoon dogs. Dev Biol (Basel) 131: 461–466.
28. Esh JB, Cunningham JG, Wiktor TJ (1982) Vaccine-induced rabies in four cats.
J Am Vet Med Assoc 180: 1336–1339.
29. Dietzschold B, Wunner WH, Wiktor TJ, Lopes AD, Lafon M, et al. (1983)
Characterization of an antigenic determinant of the glycoprotein that correlates
with pathogenicity of rabies virus. Proc Natl Acad Sci U S A 80: 70–74.
30. Ito N, Takayama M, Yamada K, Sugiyama M, Minamoto N (2001) Rescue of
rabies virus from cloned cDNA and identification of the pathogenicity-related
gene: glycoprotein gene is associated with virulence for adult mice. J Virol 75:
9121–9128.
31. Faber M, Faber ML, Papaneri A, Bette M, Weihe E, et al. (2005) A single amino
acid change in rabies virus glycoprotein increases virus spread and enhances
virus pathogenicity. J Virol 79: 14141–14148.
32. Morimoto K, Shoji Y, Inoue S (2005) Characterization of P gene-deficient rabies
virus: propagation, pathogenicity and antigenicity. Virus Res 111: 61–67.
33. Ito N, Sugiyama M, Yamada K, Shimizu K, Takayama-Ito M, et al. (2005)
Characterization of M gene-deficient rabies virus with advantages of effective
immunization and safety as a vaccine strain. Microbiol Immunol 49: 971–979.
34. Cenna J, Tan GS, Papaneri AB, Dietzschold B, Schnell MJ, et al. (2008)
Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine
vector expressing two copies of the rabies virus glycoprotein gene. Vaccine 26:
6405–6414.
35. Faber M, Li J, Kean RB, Hooper DC, Alugupalli KR, et al. (2009) Effective
preexposure and postexposure prophylaxis of rabies with a highly attenuated
recombinant rabies virus. Proc Natl Acad Sci U S A 106: 11300–11305.
36. Lindblad EB (2004) Aluminium compounds for use in vaccines. Immunol Cell
Biol 82: 497–505.
37. Benko S, Magyarics Z, Szabo A, Rajnavolgyi E (2008) Dendritic cell subtypes as
primary targets of vaccines: the emerging role and cross-talk of pattern
recognition receptors. Biol Chem 389: 469–485.
38. Wang X, Bao M, Wan M, Wei H, Wang L, et al. (2008) A CpG
oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus
vaccine. Vaccine 26: 1893–1901.
39. Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for
vaccine development. Trends Immunol 30: 23–32.
40. Ishii KJ, Akira S (2007) Toll or toll-free adjuvant path toward the optimal
vaccine development. J Clin Immunol 27: 363–371.
41. Sureau P, Perrin P (1989) The use of immunosome technology for vaccines
against rabies and other viral diseases. Eur J Epidemiol 5: 275–278.
42. Prehaud C, Takehara K, Flamand A, Bishop DH (1989) Immunogenic and
protective properties of rabies virus glycoprotein expressed by baculovirus
vectors. Virology 173: 390–399.
43. Sakamoto S, Ide T, Tokiyoshi S, Nakao J, Hamada F, et al. (1999) Studies on
the structures and antigenic properties of rabies virus glycoprotein analogues
produced in yeast cells. Vaccine 17: 205–218.
44. Gupta PK, Sharma S, Walunj SS, Chaturvedi VK, Raut AA, et al. (2005)
Immunogenic and antigenic properties of recombinant soluble glycoprotein of
rabies virus. Vet Microbiol 108: 207–214.
45. McGarvey PB, Hammond J, Dienelt MM, Hooper DC, Fu ZF, et al. (1995)
Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnol-
ogy (N Y) 13: 1484–1487.
46. Shakin-Eshleman SH, Remaley AT, Eshleman JR, Wunner WH, Spitalnik SL
(1992) N-linked glycosylation of rabies virus glycoprotein. Individual sequons
differ in their glycosylation efficiencies and influence on cell surface expression.
J Biol Chem 267: 10690–10698.
47. Fu ZF, Rupprecht CE, Dietzschold B, Saikumar P, Niu HS, et al. (1993) Oral
vaccination of racoons (Procyon lotor) with baculovirus-expressed rabies virus
glycoprotein. Vaccine 11: 925–928.
48. Ashraf S, Singh PK, Yadav DK, Shahnawaz M, Mishra S, et al. (2005) High
level expression of surface glycoprotein of rabies virus in tobacco leaves and its
immunoprotective activity in mice. J Biotechnol 119: 1–14.
49. Loza-Rubio E, Rojas E, Gomez L, Olivera MT, Gomez-Lim MA (2008)
Development of an edible rabies vaccine in maize using the Vnukovo strain. Dev
Biol (Basel) 131: 477–482.
50. Lyons A, Longfield J, Kuschner R, Straight T, Binn L, et al. (2008) A double-
blind, placebo-controlled study of the safety and immunogenicity of live, oral
type 4 and type 7 adenovirus vaccines in adults. Vaccine 26: 2890–2898.
51. Rupprecht CE, Hamir AN, Johnston DH, Koprowski H (1988) Efficacy of a
vaccinia-rabies glycoprotein recombinant virus vaccine in raccoons (Procyon
lotor). Rev Infect Dis 10 Suppl 4: S803–809.
52. Takaiwa F (2007) A rice-based edible vaccine expressing multiple T-cell epitopes
to induce oral tolerance and inhibit allergy. Immunol Allergy Clin North Am 27:
129–139.
53. Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, et al. (2002) Expression
in plants and immunogenicity of plant virus-based experimental rabies vaccine.
Vaccine 20: 3155–3164.
54. Ertl HC, Verma P, He Z, Xiang ZQ (1995) Plasmid vectors as anti-viral
vaccines. Ann N Y Acad Sci 772: 77–87.
55. Ertl HC, Xiang ZQ (1996) Genetic immunization. Viral Immunol 9: 1–9.
56. Lodmell DL, Ray NB, Ewalt LC (1998) Gene gun particle-mediated vaccination
with plasmid DNA confers protective immunity against rabies virus infection.
Vaccine 16: 115–118.
57. Perrin P, Jacob Y, Tordo N (2000) DNA-based immunization against
Lyssaviruses. Intervirology 43: 302–311.
58. Xiang Z, Ertl HC (1995) Manipulation of the immune response to a plasmid-
encoded viral antigen by coinoculation with plasmids expressing cytokines.
Immunity 2: 129–135.
59. Lodmell DL, Ray NB, Ulrich JT, Ewalt LC (2000) DNA vaccination of mice
against rabies virus: effects of the route of vaccination and the adjuvant
monophosphoryl lipid A (MPL). Vaccine 18: 1059–1066.
60. Lodmell DL, Ewalt LC, Parnell MJ, Rupprecht CE, Hanlon CA (2006) One-
time intradermal DNA vaccination in ear pinnae one year prior to infection
protects dogs against rabies virus. Vaccine 24: 412–416.
61. Osorio JE, Tomlinson CC, Frank RS, Haanes EJ, Rushlow K, et al. (1999)
Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine
17: 1109–1116.
62. Lodmell DL, Parnell MJ, Bailey JR, Ewalt LC, Hanlon CA (2001) One-time
gene gun or intramuscular rabies DNA vaccination of non-human primates:
comparison of neutralizing antibody responses and protection against rabies
virus 1 year after vaccination. Vaccine 20: 838–844.
63. Saxena S, Sonwane AA, Dahiya SS, Patel CL, Saini M, et al. (2009) Induction of
immune responses and protection in mice against rabies using a self-replicating
RNA vaccine encoding rabies virus glycoprotein. Vet Microbiol 136: 36–44.
64. Tesoro Cruz E, Feria Romero IA, Lopez Mendoza JG, Orozco Suarez S,
Hernandez Gonzalez R, et al. (2008) Efficient post-exposure prophylaxis against
rabies by applying a four-dose DNA vaccine intranasally. Vaccine 26:
6936–6944.
65. Lodmell DL, Parnell MJ, Bailey JR, Ewalt LC, Hanlon CA (2002) Rabies DNA
vaccination of non-human primates: post-exposure studies using gene gun
methodology that accelerates induction of neutralizing antibody and enhances
neutralizing antibody titers. Vaccine 20: 2221–2228.
66. Donnelly JJ, Wahren B, Liu MA (2005) DNA vaccines: progress and challenges.
J Immunol 175: 633–639.
67. Bodles-Brakhop AM, Heller R, Draghia-Akli R (2009) Electroporation for the
Delivery of DNA-based Vaccines and Immunotherapeutics: Current Clinical
Developments. Mol Ther 17: 585–592.
68. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-
1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort
analysis. Lancet 372: 1894–1905.
69. Tordo N, Foumier A, Jallet C, Szelechowski M, Klonjkowski B, et al. (2008)
Canine adenovirus based rabies vaccines. Dev Biol (Basel) 131: 467–476.
70. Bohm M, Thompson H, Weir A, Hasted AM, Maxwell NS, et al. (2004) Serum
antibody titres to canine parvovirus, adenovirus and distemper virus in dogs in
the UK which had not been vaccinated for at least three years. Vet Rec 154:
457–463.
71. Xiang Z, Li Y, Cun A, Yang W, Ellenberg S, et al. (2006) Chimpanzee
adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 12:
1596–1599.
72. Rupprecht CE, Blass L, Smith K, Orciari LA, Niezgoda M, et al. (2001) Human
infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med
345: 582–586.
73. Weyer J, Rupprecht CE, Mans J, Viljoen GJ, Nel LH (2007) Generation and
evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies.
Vaccine 25: 4213–4222.
74. Yuan Z, Zhang S, Liu Y, Zhang F, Fooks AR, et al. (2008) A recombinant
pseudorabies virus expressing rabies virus glycoprotein: safety and immunoge-
nicity in dogs. Vaccine 26: 1314–1321.
www.plosntds.org 8 September 2009 | Volume 3 | Issue 9 | e51575. Rux JJ, Kuser PR, Burnett RM (2003) Structural and phylogenetic analysis of
adenovirus hexons by use of high-resolution x-ray crystallographic, molecular
modeling, and sequence-based methods. J Virol 77: 9553–9566.
76. Tims T, Briggs DJ, Davis RD, Moore SM, Xiang Z, et al. (2000) Adult dogs
receiving a rabies booster dose with a recombinant adenovirus expressing rabies
virus glycoprotein develop high titers of neutralizing antibodies. Vaccine 18:
2804–2807.
77. Xiang ZQ, Pasquini S, Ertl HC (1999) Induction of genital immunity by DNA
priming and intranasal booster immunization with a replication-defective
adenoviral recombinant. J Immunol 162: 6716–6723.
78. Xiang ZQ, Yang Y, Wilson JM, Ertl HC (1996) A replication-defective human
adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology
219: 220–227.
79. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, Harris-McCoy KC, Hensley SE, et al.
(2007) Adenoviral vectors persist in vivo and maintain activated CD8+ T cells:
implications for their use as vaccines. Blood 110: 1916–1923.
80. Charlton KM, Artois M, Prevec L, Campbell JB, Casey GA, et al. (1992) Oral
rabies vaccination of skunks and foxes with a recombinant human adenovirus
vaccine. Arch Virol 123: 169–179.
81. Prevec L, Campbell JB, Christie BS, Belbeck L, Graham FL (1990) A
recombinant human adenovirus vaccine against rabies. J Infect Dis 161: 27–30.
82. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, et al. (2007)
Effect of preexisting immunity to adenovirus human serotype 5 antigens on the
immune responses of nonhuman primates to vaccine regimens based on human-
or chimpanzee-derived adenovirus vectors. J Virol 81: 6594–6604.
83. Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, et al. (2002) Novel,
chimpanzee serotype 68-based adenoviral vaccine carrier for induction of
antibodies to a transgene product. J Virol 76: 2667–2675.
84. Harro CD, Robertson MN, Lally MA, O’Neill LD, Edupuganti S, et al. (2009)
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1
clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 25:
103–114.
85. Appaiahgari MB, Pandey RM, Vrati S (2007) Seroprevalence of neutralizing
antibodies to adenovirus type 5 among children in India: implications for
recombinant adenovirus-based vaccines. Clin Vaccine Immunol 14: 1053–1055.
86. Wang Y, Xiang Z, Pasquini S, Ertl HC (1997) The use of an E1-deleted,
replication-defective adenovirus recombinant expressing the rabies virus
glycoprotein for early vaccination of mice against rabies virus. J Virol 71:
3677–3683.
87. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008)
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study):
a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet
372: 1881–1893.
88. Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, et al. (2008) Magnitude
and phenotype of cellular immune responses elicited by recombinant adenovirus
vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol 82:
4844–4852.
89. Magalhaes I, Sizemore DR, Ahmed RK, Mueller S, Wehlin L, et al. (2008)
rBCG induces strong antigen-specific T cell responses in rhesus macaques in a
prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS
ONE 3: e3790. doi:10.1371/journal.pone.0003790.
90. Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, et al. (2003)
Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen
with heterologous E1-deleted adenoviral vaccine carriers. J Immunol 171:
6774–6779.
91. Tatsis N, Blejer A, Lasaro MO, Hensley SE, Cun A, et al. (2007) A CD46-
binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther 15:
608–617.
92. Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10:
616–629.
93. Xiang Z, Li Y, Gao G, Wilson JM, Ertl HC (2003) Mucosally delivered E1-
deleted adenoviral vaccine carriers induce transgene product-specific antibody
responses in neonatal mice. J Immunol 171: 4287–4293.
94. Zhou D, Cun A, Li Y, Xiang Z, Ertl HC (2006) A chimpanzee-origin adenovirus
vector expressing the rabies virus glycoprotein as an oral vaccine against
inhalation infection with rabies virus. Mol Ther 14: 662–672.
95. Zhang S, Liu Y, Fooks AR, Zhang F, Hu R (2008) Oral vaccination of dogs
(Canis familiaris) with baits containing the recombinant rabies-canine adeno-
virus type-2 vaccine confers long-lasting immunity against rabies. Vaccine 26:
345–350.
96. Liu Y, Zhang S, Ma G, Zhang F, Hu R (2008) Efficacy and safety of a live
canine adenovirus-vectored rabies virus vaccine in swine. Vaccine 26:
5368–5372.
97. Shmarov MM, Tutykhina IL, Logunov D, Verkhovskai LV, Nedosekov VV, et al.
(2006) [The induction of protective immune response in mice vaccinated by
recombinant avian adenovirus CELO expressing glycoprotein G of the rabies
virus]. Zh Mikrobiol Epidemiol Immunobiol: 69–71.
www.plosntds.org 9 September 2009 | Volume 3 | Issue 9 | e515